89451-57-0

Upstream product

• 27806-90-2 1,2-dimethyl-4-piperidone iodomethylate 
• 2627-86-3 (S)-1-phenyl-ethylamine 
• 103539-59-9 1-butyl-2-methyl-4-piperidone methiodide 
• 2627-86-3 (-)-α-methylbenzylamine 
• 13604-71-2 1-butyl-2-methyl-4-piperidone 
• 89467-37-8 (R)-2-methyl-1-((S)-1-phenylethyl)piperidin-4-one 
• 89467-36-7 1-α-phenylethyl-2-methyl-4-piperidone 

Downstream Products

• 89451-59-2 (2R,4R)-2-methylpiperidin-4-ol 
• 89451-58-1 (+)-cis-2-methyl-4-piperidol 

Relevant academic research and scientific papers

FIRST ASYMMETRIC SYNTHESIS OF 4-PIPERIDONES. PREPARATION OF OPTICALLY ACTIVE DIASTEREOMERS OF 1-α-PHENYLETHYL-2-METHYL-4-PIPERIDONE

The fundamental possibility of carrying out the asymmetric synthesis of 4-piperidones on the basis of the transamination of 1-substituted 2-methyl-4-piperidone methiodides by optically active α-phenylethylamine was demonstrated; the optical yield of the asymmetric transamination is 50percent.The occurrence of asymmetric synthesis was confirmed by the isolation of enantiomers of 2-methyl-4-piperidol by reduction of the individual diastereomers of 1-α-phenyl-ethyl-2-methyl-4-piperidone to the corresponding 4-piperidols with subsequent removal of the chiral substituent attached to the nitrogen atom.

(PIPERIDINYLOXY)PHENYL, (PIPERIDINYLOXY)PYRIDINYL, (PIPERIDINYLSULFANYL)PHENYL AND (PIPERIDINYLSULFANYL)PYRIDINYL COMPOUNDS AS 5-HT1F AGONISTS

The present invention relates to compounds of formula 1: and pharmaceutically acceptable acid addition sails thereof. The compounds of the present invention are useful for activating 5-HTIF receptors, inhibiting neuronal protein extravasation, and for the treatment or preverition of migraine in mammals, particularly humans.